Lumbosacral plexus lesion

Summary

Lumbosacral plexus lesion (MONDO:0001829) is a disease. A subtype of nerve plexus disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	lumbosacral plexus lesion
Mondo ID	MONDO:0001829
DOID	DOID:13913
SNOMED CT	4062006
UMLS	C0154735
MedGen	509637
GARD	0023017
Anatomy (UBERON)	UBERON:0001815
Is cancer (heuristic)	no

Also known as: lumbosacral nerve plexus nerve plexus disease · lumbosacral plexus lesions · nerve plexus disease of lumbosacral nerve plexus

Disease family

This is a subtype of nerve plexus disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › peripheral nervous system disorder › peripheral neuropathy › nerve plexus disorder › lumbosacral plexus lesion

Related subtypes (3): nerve plexus neoplasm, brachial plexus neuropathy, radiation-induced plexopathy

Subtypes (3): lesion of sciatic nerve, lumbar plexus neoplasm, sacral nerve plexus disorder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.